Advertisement

Utilization of a uniform grading system for interpreting serous ovarian cancer

      Objective

      The purpose of the study was to implement a uniform system for assigning tumor grade in serous ovarian cancer and evaluate its correlation with response to conventional chemotherapy.

      Study Design

      Serous ovarian cancer tumor samples were retrospectively reviewed by 3 pathologists who were blinded to the original report. Samples were scored for architectural pattern, nuclear pleomorphism, and mitotic activity. Sum scores from these 3 indices were used to classify tumors as low grade or high grade.

      Results

      A total of 21 patients were identified as low-grade tumors and 21 were identified as high-grade tumors. Of low-grade tumors, 16 (76%) were found to be platinum resistant, defined as recurrent or persistent disease, 180 days from completion of the final cycle of chemotherapy, Of 21 patients defined as high grade, 9 (43%) were platinum resistant (P = .028).

      Conclusion

      Utilization of a uniform grading system retrospectively correlates with platinum sensitivity.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jemal A.
        • Siegel R.
        • Ward E.
        • Murray T.
        • Xu J.
        • Thun M.J.
        Cancer statistics, 2007.
        CA Cancer J Clin. 2007; 57: 43-66
        • McGuire W.P.
        • Hoskins W.J.
        • Brady M.F.
        • et al.
        Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
        N Engl J Med. 1996; 334: 1-6
        • Blackledge G.
        • Lawton F.
        • Redman C.
        • Kelly K.
        Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design of phase II trials.
        Br J Cancer. 1989; 59: 650-653
        • Gore M.E.
        • Fryatt I.
        • Wiltshaw E.
        • Dawson T.
        Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.
        Gynecol Oncol. 1990; 36: 207-211
        • Markman M.
        • Rothman R.
        • Hakes T.
        • et al.
        Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
        J Clin Oncol. 1991; 9: 389-393
        • Ozols R.F.
        • Garvin A.J.
        • Costa J.
        • Simon R.M.
        • Young R.C.
        Advanced ovarian cancer: Correlation of histologic grade with response to therapy and survival.
        Cancer. 1980; 45: 572-581
        • Thigpen J.T.
        • Blessing J.A.
        • Ball H.
        • Hummel S.J.
        • Barrett R.J.
        Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study.
        J Clin Oncol. 1994; 12: 1748-1753
        • Baak J.P.
        • Chan K.K.
        • Stolk J.G.
        • Kenemans P.
        Prognostic factors in borderline and invasive ovarian tumors of the common epithelial type.
        Pathol Res Pract. 1987; 182: 755-774
        • Dembo A.J.
        • Davy M.
        • Stenwig A.E.
        • Berle E.J.
        • Bush R.S.
        • Kjorstad K.
        Prognostic factors in patients with stage I epithelial ovarian cancer.
        Obstet Gynecol. 1990; 75: 263-273
        • Eisenhauer E.A.
        • Vermorken J.B.
        • van G.M.
        Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients.
        Ann Oncol. 1997; 8: 963-968
        • Farias-Eisner R.
        • Teng F.
        • Oliveira M.
        • et al.
        The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery.
        Gynecol Oncol. 1994; 55: 108-110
        • Friedlander M.L.
        • Dembo A.J.
        Prognostic factors in ovarian cancer.
        Semin Oncol. 1991; 18: 205-212
        • Malkasian Jr, G.D.
        • Melton III, L.J.
        • O'Brien P.C.
        • Greene M.H.
        Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary.
        Am J Obstet Gynecol. 1984; 149: 274-284
        • Malpica A.
        • Deavers M.T.
        • Lu K.
        • et al.
        Grading ovarian serous carcinoma using a two-tier system.
        Am J Surg Pathol. 2004; 28: 496-504
        • Mayr D.
        • Diebold J.
        Grading of ovarian carcinomas.
        Int J Gynecol Pathol. 2000; 19: 348-353
        • Omura G.A.
        • Brady M.F.
        • Homesley H.D.
        • et al.
        Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience.
        J Clin Oncol. 1991; 9: 1138-1150
        • Shimizu Y.
        • Kamoi S.
        • Amada S.
        • Hasumi K.
        • Akiyama F.
        • Silverberg S.G.
        Toward the development of a universal grading system for ovarian epithelial carcinoma.
        Gynecol Oncol. 1998; 70: 2-12
        • Shimizu Y.
        • Kamoi S.
        • Amada S.
        • Akiyama F.
        • Silverberg S.G.
        Toward the development of a universal grading system for ovarian epithelial carcinoma: Testing of a proposed system in a series of 461 patients with uniform treatment and follow-up.
        Cancer. 1998; 82: 893-901
        • Silverberg S.G.
        Prognostic significance of pathologic features of ovarian carcinoma.
        Curr Top Pathol. 1989; 78: 85-109
        • Sorbe B.
        • Frankendal B.
        • Veress B.
        Importance of histologic grading in the prognosis of epithelial ovarian carcinoma.
        Obstet Gynecol. 1982; 59: 576-582
        • Ross J.S.
        • Yang F.
        • Kallakury B.V.
        • Sheehan C.E.
        • Ambros R.A.
        • Muraca P.J.
        HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary.
        Am J Clin Pathol. 1999; 111: 311-316
        • Munoz K.A.
        • Harlan L.C.
        • Trimble E.L.
        Patterns of care for women with ovarian cancer in the United States.
        J Clin Oncol. 1997; 15: 3408-3415
      1. Classification and staging of malignant tumours in the female pelvis.
        Acta Obstet Gynecol Scand. 1971; 50: 1-7
        • Baak J.P.
        • Delemarre J.F.
        • Langley F.A.
        • Talerman A.
        Grading ovarian tumors.
        Anal Quant Cytol Histol. 1986; 8: 349-353
        • Bichel P.
        • Jakobsen A.
        A new histologic grading index in ovarian carcinoma.
        Int J Gynecol Pathol. 1989; 8: 147-155
        • Cramer S.F.
        • Roth L.M.
        • Ulbright T.M.
        • et al.
        Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers.
        Arch Pathol Lab Med. 1987; 111: 819-829
        • Geppert M.
        • Smyczek-Gargya B.
        Morphologic criteria for the prognosis of serous cystadenocarcinoma of the ovary.
        Gynecol Obstet Invest. 1995; 39: 136-140
        • Hernandez E.
        • Rosenshein N.B.
        • Bhagavan B.S.
        • Parmley T.H.
        Tumor heterogeneity and histopathology in epithelial ovarian cancer.
        Obstet Gynecol. 1984; 63: 330-334
        • Seidman J.D.
        • Horkayne-Szakaly I.
        • Cosin J.A.
        • et al.
        Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.
        Gynecol Oncol. 2006; 103: 703-708
        • Baak J.P.
        • Langley F.A.
        • Talerman A.
        • Delemarre J.F.
        Interpathologist and intrapathologist disagreement in ovarian tumor grading and typing.
        Anal Quant Cytol Histol. 1986; 8: 354-357
        • Hernandez E.
        • Bhagavan B.S.
        • Parmley T.H.
        • Rosenshein N.B.
        Interobserver variability in the interpretation of epithelial ovarian cancer.
        Gynecol Oncol. 1984; 17: 117-123
        • Malpica A.
        • Deavers M.T.
        • Tornos C.
        • et al.
        Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma.
        Am J Surg Pathol. 2007; 31: 1168-1174
        • Stalsberg H.
        • Abeler V.
        • Blom G.P.
        • Bostad L.
        • Skarland E.
        • Westgaard G.
        Observer variation in histologic classification of malignant and borderline ovarian tumors.
        Hum Pathol. 1988; 19: 1030-1035
        • Cohen J.
        A coefficient of agreement for nominal scales.
        Educ Psychol Meas. 1960; 20: 37-46
        • Reles A.
        • Wen W.H.
        • Schmider A.
        • et al.
        Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
        Clin Cancer Res. 2001; 7: 2984-2997
        • Laframboise S.
        • Chapman W.
        • McLaughlin J.
        • Andrulis I.L.
        p53 mutations in epithelial ovarian cancers: Possible role in predicting chemoresistance.
        Cancer J. 2000; 6: 302-308
        • Havrilesky L.
        • Darcy M.
        • Hamdan H.
        • et al.
        Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: A Gynecologic Oncology Group Study.
        J Clin Oncol. 2003; 21: 3814-3825
        • Wong K.K.
        • Lu K.H.
        • Malpica A.
        • et al.
        Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis.
        Int J Gynecol Pathol. 2007; 26: 404-409
        • Eltabbakh G.H.
        • Belinson J.L.
        • Kennedy A.W.
        • et al.
        p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer.
        Cancer. 1997; 80: 892-898
        • Hartmann L.C.
        • Podratz K.C.
        • Keeney G.L.
        • et al.
        Prognostic significance of p53 immunostaining in epithelial ovarian cancer.
        J Clin Oncol. 1994; 12: 64-69
        • Gershenson D.M.
        • Sun C.C.
        • Lu K.H.
        • et al.
        Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
        Obstet Gynecol. 2006; 108: 361-368
        • Shvartsman H.S.
        • Sun C.C.
        • Bodurka D.C.
        • et al.
        Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma.
        Gynecol Oncol. 2007; 105: 625-629